Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/26/2025

Management of Alendronate-Induced Severe GERD

Alternative Osteoporosis Therapies

  • The American College of Rheumatology conditionally recommends PTH/PTHrP agonists (teriparatide or abaloparatide) over anti-resorptives for very high fracture risk patients, as these are superior for very high-risk patients 3, 4
  • IV bisphosphonates (zoledronic acid or ibandronate) are recommended as first-line alternatives to oral alendronate, as they bypass the esophagus entirely and eliminate upper GI irritation risk, with zoledronic acid given yearly and ibandronate IV given every 3 months 1, 2
  • Denosumab (subcutaneous every 6 months) is conditionally recommended for high or moderate fracture risk patients, as it avoids GI exposure entirely 3, 4

Concurrent GERD Management

  • The American Gastroenterological Association emphasizes that PPIs are safe for GERD treatment, and recommends initiating or optimizing PPI therapy (single daily dose for 4-8 weeks, escalating to twice daily if needed) to treat alendronate-induced esophageal injury and underlying GERD 5, 6
  • PPIs are more effective than H2-receptor antagonists for healing esophagitis and symptom relief, with a Grade B recommendation for weight loss if overweight/obese for improving GERD outcomes 7, 8

Important Considerations

  • Ensure adequate bone protection by checking vitamin D levels and correcting deficiency before starting any bisphosphonate, with a target 25(OH)D level >32 ng/mL, and ensure adequate calcium and vitamin D intake 1, 2
  • Consider a drug holiday if the patient had been on alendronate for ≥5 years, as the FLEX trial demonstrated continued fracture protection for up to 5 years after discontinuation, particularly for patients with limited life expectancy or lower fracture risk 9, 10
  • Reassess BMD with vertebral fracture assessment every 1-2 years during osteoporosis therapy, and monitor for resolution of GERD symptoms after alendronate discontinuation and PPI initiation 3, 4, 5, 6

REFERENCES